Laura Bessen Buys Shares of C4 Therapeutics, Inc.

On June 24, 2026, Laura Bessen, an insider at C4 Therapeutics, Inc. (NasdaqGS: CCCC), bought 62,000 shares of the company. The transaction did not disclose a specific price or total value.

Insider Buying and Selling at C4 Therapeutics, Inc.

In addition to Laura Bessen, several other insiders, including Steven Hoerter, Stephen Fawell, Owen Hughes, Donna Roy Grogan, and Kenneth Carl Anderson, purchased shares of C4 Therapeutics on the same date. Each bought 62,000 shares, except for Kenneth Carl Anderson, who acquired 1,070 shares at $2.11 per share. None of these transactions were planned under Rule 10b5-1.

Other Institutional Activity in C4 Therapeutics

Morgan Stanley increased its holdings in C4 Therapeutics by 90,738 shares, bringing its total to 9,072,400 shares worth approximately $23.9 million. RA Capital Management, L.P. maintained its position at 8,000,000 shares valued at $21.0 million. Bain Capital Life Sciences Investors, LLC also held steady at 7,171,910 shares with a value of $18.9 million. Lynx1 Capital Management LP reduced its stake by 99,231 shares, resulting in a total of 6,998,902 shares worth $18.4 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at $10.2 million.

C4 Therapeutics, Inc. Stock Up 10.6%

Shares of C4 Therapeutics, Inc. traded near $4.40 on Saturday. The company has a market capitalization of about $471 million. While it does not have a meaningful forward P/E ratio due to its lack of profitability, it has a beta of 2.93, indicating higher volatility compared to the market. The stock's 52-week range is between $1.40 and $4.60, with a 50-day moving average of $3.51 and a 200-day moving average of $2.70. The company's current ratio is 9.00, and its quick ratio is 8.76, suggesting strong liquidity.

Analysts Set New Price Targets

On June 1, 2026, Evercore ISI Group maintained its buy rating for C4 Therapeutics, setting a price target of $12. Barclays also maintained a buy rating with a target of $7 set on February 27, 2026. Brookline Capital reiterated its buy rating with the highest price target of $30 on February 23, 2026. Analysts collectively have a strong buy consensus for C4 Therapeutics, with a mean target price of $13.33 based on six analyst opinions.

About C4 Therapeutics

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing treatments that target and degrade disease-causing proteins. The company's lead product, Cemsidomide, is in clinical trials for multiple myeloma. Other projects include treatments for non-small cell lung cancer and conditions related to inflammation and neurodegeneration. C4 Therapeutics collaborates with various partners, including Roche and Merck KGAA.

Bottom Line

Laura Bessen's purchase of C4 Therapeutics shares adds to a series of insider buys, suggesting confidence in the company's prospects. Investors often track such insider activity as a potential indicator of a company's future performance. It's important to note that 13F filings and insider transactions are backward-looking and may not reflect the current positions or intentions of the investors involved.